BioCentury | Mar 13, 2019
Distillery Therapeutics

IKKβ inhibition for tendinopathy

...work includes testing IKKβ inhibition in a rat model of rotator cuff tendinopathy and repair. IMMD Inc....
BioCentury | Jul 31, 2017
Distillery Therapeutics

Endocrine / Metabolic

...obesity. Daiichi Sankyo Co. Ltd. has PLX5622 in Phase I testing to treat rheumatoid arthritis. IMMD Inc....
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Various

...survival compared with vehicle. Next steps could include studies in additional models of thrombosis-related diseases. IMMD Inc....
BioCentury | Jun 12, 2014
Distillery Therapeutics

Indication: Various

...inhibit IKBKB. Sanofi's IKBKB inhibitor, SAR113945, is in Phase II testing to treat osteoarthritis (OA). IMMD Inc....
Items per page:
1 - 4 of 4
BioCentury | Mar 13, 2019
Distillery Therapeutics

IKKβ inhibition for tendinopathy

...work includes testing IKKβ inhibition in a rat model of rotator cuff tendinopathy and repair. IMMD Inc....
BioCentury | Jul 31, 2017
Distillery Therapeutics

Endocrine / Metabolic

...obesity. Daiichi Sankyo Co. Ltd. has PLX5622 in Phase I testing to treat rheumatoid arthritis. IMMD Inc....
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Various

...survival compared with vehicle. Next steps could include studies in additional models of thrombosis-related diseases. IMMD Inc....
BioCentury | Jun 12, 2014
Distillery Therapeutics

Indication: Various

...inhibit IKBKB. Sanofi's IKBKB inhibitor, SAR113945, is in Phase II testing to treat osteoarthritis (OA). IMMD Inc....
Items per page:
1 - 4 of 4